pancreatic cancer and semaglutide What to know about new study showing weight loss drugs can lower risk Your pancreas may be making

In a retrospective analysis of 177 patients on oral semaglutide, weight loss velocity decelerates sharply after 3 months from 1.99 kg/month in the first month to 0.18 kg/month between months 6 and 12 and a 23% weight rebound is already measurable by month 18 (Makkar et al., 2026)

For dosing in your experiments, a U-100 insulin syringe (typically 1 mL, 0.5 mL, or 0.3 mL) is the standard choice due to its fine, easy-to-read unit markings

73 Another report mentioned trials in Crohns disease and even in multiple sclerosis , suggesting potential benefits

How Common Is Constipation on Retatrutide

berry flavor makes daily routine enjoyable

The Ozempic NAION lawsuit involves claims that Ozempic and other GLP-1 drugs may increase the risk of a serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which occurs when blood flow to the optic nerve is disturbed or cut off